CC chemokine ligands in patients presenting with stable chest pain: association with atherosclerosis and future cardiovascular events

M O Versteylen, M Manca, I A Joosen, D E Schmidt, M Das, L Hofstra, H J Crijns, E A Biessen, B L Kietselaer

Research output: Contribution to journalArticleProfessional

Abstract

BACKGROUND: CC chemokine ligands (CCLs) are elevated during acute coronary syndrome (ACS) and correlate with secondary events. Their involvement in plaque inflammation led us to investigate whether CCL3-5-18 are linked to the extent of coronary artery disease (CAD) and prognostic for primary events during follow-up.

METHODS: We measured CCL3-5-18 serum concentrations in 712 patients with chest discomfort referred for cardiac CT angiography. Obstructive CAD was defined as ≥50 % stenosis. The extent of CAD was measured by calcium score and segment involvement score (number of coronary segments with any CAD, range 0-16). Patients were followed up for all-cause mortality, ACS and revascularisation, for a mean 26 ± 7 months.

RESULTS: Patients with obstructive CAD had significantly higher CCL5 (p = 0.02), and borderline significantly elevated CCL18 plasma levels as compared with patients with <50 % stenosis (p = 0.06). CCL18 levels were associated with coronary calcification (p = 0.002) and segment involvement score (p = 0.007). Corrected for traditional risk factors, only CCL5 provided independent predictive value for obstructive CAD: odds ratio (OR) 1.27 (1.02-1.59), p = 0.04. CCL5 provided independent predictive value for primary events during follow-up: OR 1.62 (1.03-2.57), p = 0.04.

CONCLUSIONS: While CCL18 serum levels correlated with extent of CAD, CCL5 demonstrated an independent association with the presence of obstructive CAD, and occurrence of primary cardiac events.

Original languageEnglish
Pages (from-to)722-729
Number of pages8
JournalNetherlands Heart Journal
Volume24
Issue number12
DOIs
Publication statusPublished - Dec 2016

Cite this